Raj Reddy
Chief Executive Officer Canary Cure Therapeutics
Dr. Raj Reddy is a distinguished pharmacologist and pharmaceutical industry veteran serving as the Founder and CEO of Canary Cure Therapeutics. With a career dedicated to overcoming the fundamental biological barriers of drug delivery, Dr. Reddy is a recognized expert in metabolic disease biology and adipose tissue genetics. He is a prolific inventor holding over 30 patents in molecular biology and advanced lipid nanoparticle (LNP) engineering, including the proprietary Hyper-15™ “Inverse Chimera” platform with a novel active fusion core.
Prior to founding Canary Cure, Dr. Reddy led strategic R&D initiatives focused on translating complex genetic modalities into clinical realities. His recent work targets the industry’s most critical bottleneck: unlocking receptor-independent cytosolic delivery in “endocytically quiet” tissues such as mature skeletal muscle and subcutaneous fat. By pivoting from passive endocytosis to active biophysical fusion, Dr. Reddy’s innovations are redefining the therapeutic possibilities for obesity, sarcopenia, and neuromuscular disorders. His vision is to establish a new paradigm in genetic medicine where delivery is no longer the rate-limiting step for clinical efficacy.
Seminars
- What are the remaining barriers for achieving efficient, organ-specific delivery to difficult targets?
- Which design strategies and technologies are most promising for enabling precise extrahepatic targeting while minimizing liver accumulation?
- What unmet therapeutic needs could next-generation extrahepatic LNPs address to expand the RNA, gene editing, and cell therapy landscape?
- Redefining the LNP Core (The “Active Fusion Core”): Introducing the Hyper-15™ Active Fusion LNP. Liver Detargeting & Safety: The technology reduces reliance on toxic cationic lipids. This not only improves the safety profile but effectively allows the payload to bypass the liver, addressing a key challenge in the current therapeutic landscape.
- Bypassing the “Acidification Trap”: While standard LNPs lose >98% of cargo to endosomal degradation, Hyper-15™ completely bypasses the endocytic pathway. By forcing active, instantaneous fusion at the plasma membrane surface, we demonstrate the ability to achieve 100% cytosolic bioavailability of genetic payloads without requiring pH-dependent acidification or receptor upregulation
- Unlocking “Endocytically Quiet” Tissue: Presenting breakthrough efficacy data in Human Skeletal Muscle Myotubes and Adipocytes. We show how this mechanical fusion mechanism successfully transfects mature, non-dividing tissues that are impenetrable to standard LNPs, overcoming the industry’s longest-standing delivery bottleneck in metabolic and neuromuscular disease
